Fig. 8From: Nanotechnology based solutions for anti-leishmanial impediments: a detailed insightGraph plotted against mean plasma concentration (ng/ml) of Amp-B and time (h) clearly demonstrating improved intestinal absorption and bioavailability of Amp-B followed by oral administration (Dose = 10 mg/kg) of Amp-B-PLGA NPs (F1-PO) in comparison to Fungizone®-PO in healthy rats [147] Back to article page